Molecular Size and Sublingual Absorption: Why Dalton Count Decides the Route

Short answer: Yes — molecular size is the single best first-pass predictor of whether a compound is a plausible sublingual candidate, and the Dalton math explains why the whole sublingual category is built the way it is. Small, uncharged molecules are the friendly cases; large or charged ones need formulation help. Size predicts plausibility, never a percentage.

Ask "does sublingual work?" and you end up at the same place every time: how big is the molecule? This article assembles the size table the supplement industry rarely prints — the actual molecules people buy, in Daltons — and shows what size can and cannot tell you. It pairs with our per-compound breakdown of which peptides suit the sublingual route and the broader sublingual delivery science guide.

The membrane is selective — and that's good news for small molecules

The tissue under your tongue is thin, well-perfused, and built to let the right things through. Standard pharmacology: passive mucosal permeation depends on molecular size, electrical charge, and lipophilicity (fat-solubility). Small, uncharged, moderately lipophilic molecules diffuse across relatively easily. Large or charged molecules need transporters, formulation help, or a different route.

A Dalton (Da) is just the unit of molecular mass. Orientation points: water is 18 Da, glucose 180 Da, a small peptide a few hundred, a large peptide several thousand. There's no single magic cutoff — charge and lipophilicity move the line — but the gradient is consistent, and a working rule of thumb in formulation circles puts the friendly zone for mucosal diffusion at roughly 500 Da and below. Below that line, the membrane is a plausible door; above it, it becomes a wall you have to engineer around.

The NAD-family size table

The clearest real-world illustration is the NAD+ family, because the entire precursor market exists because of size and charge. Figures per the research dossier's verified size table (research-dossier:51):

Read top to bottom and the gradient does the talking: niacinamide sits comfortably inside the friendly zone; NMN and NR straddle the borderline; intact NAD+ is over the line and carries a charge — a double strike against mucosal absorption.

Where the peptides land

Now the fun part — mapping the compounds people actually buy onto the same scale, as plain chemistry:

• KPV, ~341 Da. A tripeptide well inside the friendly zone. On size alone, KPV is one of the best structural candidates in the entire sublingual catalog. (In this catalog it lives inside the KLOW blend — see which peptides suit sublingual.)
• GHK-Cu. A small copper tripeptide in the same few-hundred-Da neighborhood — again, an excellent size fit.
• BPC-157, ~1,420 Da. A 15-amino-acid chain, comfortably above the friendly zone. And yet BPC-157 has its own ace: it's gastric-stable and survives the gut (research-dossier:55) [preclinical evidence], so it doesn't depend on the mucosa the way fragile peptides do.
• Large peptides — TB-500, the CJC-1295 class, MOTS-c, Thymosin Alpha-1 — are big, protease-fragile molecules where the size math is least favorable.

Why big molecules still get a sublingual shot

Here's the subtlety a size-only reading misses: for large peptides, size isn't even the binding constraint — gut proteases are. These molecules are dismantled in the stomach before absorption, so sublingual delivery isn't competing against a working gut route; it's the only plausible needle-free route at all. Size tells you the mucosa is a hard barrier for them; protease fragility tells you the gut is a harder one. That's why formulators reach for enhancers — cyclodextrins, lecithin, tight-junction modulators — covered in our permeation enhancers explainer. Enhancers exist precisely to fudge what raw molecular properties predict.

The NAD+ double bind

Intact NAD+ faces a second problem stacked on its size: it does not survive the gut (research-dossier:53). Its precursors, NMN and NR, are orally bioavailable and raise blood NAD+ in human studies (Trammell et al., 2016, for NR; multiple NMN trials) [published human data].

That combination — gut route fails, mucosal route is size-unfriendly — is exactly what motivated sublingual NAD+ formats like the NAD+ strip: an attempt to route around gauntlet one. Whether the membrane accepts a 663 Da charged molecule in meaningful quantities, with or without formulation help, is the open gauntlet two.

Where the map ends

One honest limit, plainly: no published size-to-absorption curve exists for any strip product. Nobody has measured "X Da means Y% absorbed" for a peptide or supplement strip in humans, and charge and lipophilicity can move the line in either direction — a charged 300 Da molecule can be a worse candidate than an uncharged 500 Da one. Size is a screening tool, the best first filter we have. It is not a delivery guarantee, and anyone quoting you a size-derived absorption percentage is extrapolating past the literature.

The bottom line

Size is the smartest first question you can ask about any sublingual product — and the table above gives you the answers the labels don't. Small molecules like KPV (~341 Da) and the NAD precursors are natural fits; mid-size gastric-stable peptides like BPC-157 (~1,420 Da) get a dual-route advantage; the big fragile peptides are where formulation earns its keep. Know the Dalton count and you can read any strip's pitch with informed eyes — that's most of the game.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.